Affymetrix to Repurchase $95.5M of Senior Notes as Part of Settlement | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Affymetrix has settled a legal dispute with holders of the company's 3.50 percent senior notes, and as part of the settlement it has agreed to start within two weeks a tender offer to repurchase the entire $95.5 million aggregate principal amount of the notes currently outstanding plus accrued interest, it said in a document filed with the US Securities and Exchange Commission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.